
Menlo’s excellent healthcare report confirms the trend we have been backing. The first wave of healthcare AI automated paperwork, and incumbents are now collecting most of the returns: v. interesting to read Epic and Microsoft took roughly two of every three new scribe dollars this year. The second wave is harder and more valuable and that’s where we’ve been focusing. Life-sciences AI spend grew 23x. Half of pharma now runs AI at scale, up from 15% a year ago. Clinical copilots grew 5.5x, while scribes grew 1.6x. Lasting companies will be built where incumbents have less of a head start and the full benefits of AI are most clearly felt - i.e. discovery, trials and clinical decision-making. This work needs proprietary data, deep science and/or products judged on patient outcomes rather than hours saved. Those advantages are hard to copy and startups are well placed to focus here. Sceptics (and there’s a lot out there) will point out that a minority of pharma leaders expect an AI-discovered drug to be approved within two years. I see that as a sign of how early the market is and with the underlying models being as bad today as they ever will be the chance that we see huge advancements here is inevitable, imho. The startups that generate the data and earn trust now have the opportunity to create huge value. Europe’s science base combined with its deep technical experience in AI gives its founders a real shot at this. We’ve been fortunate to already partner with some exceptional companies (Lindus, Uncovr, Apoha, Sano, Dalton, Sable, Inovia, Verisian, Resolyst, Outpost bio and many more) and look forward to meeting many more founders building for the future of healthcare in the era of AI @seedcamp















